<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1411211311
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Pergoveris
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FOLLITROPIN ALFA,LUTROPIN ALFA
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        450,225
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        IU
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection in pre-filled pen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled pen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Restricted
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        911.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MERCK SERONO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MERCK SERONO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Merck Europe BV
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G03GA30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Pergoveris is</strong></p><p dir="ltr">Pergoveris contains two different active substances called &ldquo;follitropin alfa&rdquo; and &ldquo;lutropin alfa&rdquo;. Both belong to the family of hormones called &ldquo;gonadotropins&rdquo;, which are involved in reproduction and fertility.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>What Pergoveris is used for</strong></p><p dir="ltr">This medicine is used to stimulate the development of follicles (each containing an egg) in your ovaries. This is to help you get pregnant. It is for use in adult women (18&nbsp;years old or above) who have low levels (severe deficiency) of &ldquo;follicle stimulating hormone&rdquo; (FSH) and &ldquo;luteinising hormone&rdquo; (LH). These women are usually infertile.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>How Pergoveris works</strong></p><p dir="ltr">The active substances in Pergoveris are copies of the natural hormones FSH and LH. In your body:</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; FSH stimulates the production of eggs</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LH stimulates the release of the eggs.</p><p dir="ltr">&nbsp;</p><p dir="ltr">By replacing the missing hormones, Pergoveris allows women with low levels of FSH and LH to develop a follicle. This will then release an egg, after an injection of the hormone &ldquo;human chorionic gonadotropin (hCG)&rdquo;. This helps the women to become pregnant.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">You and your partner&#39;s fertility should be evaluated before the treatment is started by a doctor experienced in treating fertility problems.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Do not use Pergoveris</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to follicle stimulating hormone (FSH), luteinising hormone (LH) or any of the other ingredients of this medicine (listed in section&nbsp;6)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a brain tumour (in your hypothalamus or pituitary gland)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have large ovaries or sacs of fluid within your ovaries (ovarian cysts) of unknown origin</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have unexplained vaginal bleeding</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have cancer in your ovaries, womb or breasts</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a condition that would make a normal pregnancy impossible, such as an early menopause, malformed sex organs or benign tumours of the womb.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Do not use this medicine if any of the above apply to you. If you are not sure, talk to your doctor, pharmacist or nurse before using this medicine.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Warnings and precautions</strong></p><p dir="ltr">Talk to your doctor, pharmacist or nurse before using Pergoveris.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><u>Porphyria</u></p><p dir="ltr">Talk to your doctor before you start your treatment.If you or any member of your family have porphyria (an inability to breakdown porphyrins that may be passed on from parents to children).</p><p dir="ltr">Tell your doctor straight away if:</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your skin becomes fragile and easily blistered, especially skin that has been frequently exposed to sunlight</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have stomach, arm or leg pain.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In case of above events your doctor may recommend that you stop treatment.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Ovarian hyperstimulation syndrome (OHSS)</u></p><p dir="ltr">This medicine stimulates your ovaries. This increases your risk of developing ovarian hyperstimulation syndrome (OHSS). This is when your follicles develop too much and become large cysts. If you get lower abdominal pain, gain any weight rapidly, feel sick or are vomiting or if you have difficulty in breathing, talk to your doctor straight away. They might ask you to stop using this medicine (see in section&nbsp;4. under &ldquo;Most serious side effects&rdquo;).</p><p dir="ltr">&nbsp;</p><p dir="ltr">In case you are not ovulating and if the recommended dose and schedule of administration are adhered to, the occurrence of severe OHSS is less likely. Pergoveris treatment seldom causes severe OHSS. This becomes more likely if the medicine that is used for final follicular maturation (containing human chorionic gonadotrophin, hCG) is administered (see in section&nbsp;3. under &ldquo;How much to use&rdquo; for details). If you are developing OHSS your doctor may not give you any hCG in this treatment cycle and you may be told not to have sex or that you should use a barrier contraceptive method for at least four days.</p><p dir="ltr">Your doctor will ensure, careful monitoring of the ovarian response, based on ultrasound and blood tests (oestradiol measurements) before and during the course of treatment.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Multiple pregnancy</u></p><p dir="ltr">When using Pergoveris, you have a higher risk of being pregnant with more than one child at the same time (&ldquo;multiple pregnancy&rdquo;, mostly twins), than if you conceived naturally. Multiple pregnancy may lead to medical complications for you and your babies. You can reduce the risk of multiple pregnancy by using the right dose of Pergoveris at the right times.</p><p dir="ltr">&nbsp;</p><p dir="ltr">To minimise the risk of multiple pregnancy, ultrasound scans as well as blood tests are recommended.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Miscarriage</u></p><p dir="ltr">When undergoing stimulation of your ovaries to produce eggs, you are more likely to have a miscarriage than the average woman.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Ectopic pregnancy</u></p><p dir="ltr">Women who have ever had blocked or damaged fallopian tubes (tubal disease) are at risk of pregnancy where the embryo is implanted outside the womb (ectopic pregnancy). This is whether the pregnancy is obtained by spontaneous conception or with fertility treatments.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Blood clotting problems (thromboembolic events)</u></p><p dir="ltr">Talk to your doctor before using Pergoveris if you or a member of your family have ever had blood clots in the leg or in the lung, or a heart attack or stroke. You may be at a higher risk of serious blood clots or existing clots might become worse with Pergoveris treatment.</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><u>Tumours of sex organs</u></p><p dir="ltr">There have been reports of tumours in the ovaries and other sex organs, both benign and malignant, in women who have undergone multiple regimens for infertility treatment.</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><u>Allergic reactions</u></p><p dir="ltr">There have been isolated reports of non-serious allergic reactions to Pergoveris. If you have ever had this type of reaction to a similar medicine, talk to your doctor before using Pergoveris.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Children and adolescents</strong></p><p dir="ltr">Pergoveris is not for use in children and adolescents below 18&nbsp;years old.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Other medicines and Pergoveris</strong></p><p dir="ltr">Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Do not use Pergoveris with other medicines in the same injection. You can use Pergoveris with a licensed follitropin alfa preparation as separate injections, if prescribed by your doctor.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Pregnancy and breast-feeding</strong></p><p dir="ltr">Do not use Pergoveris if you are pregnant or breast-feeding.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Driving and using machines</strong></p><p dir="ltr">It is not expected that this medicine will affect your ability to drive or use machines.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Pergoveris contains sodium</strong></p><p dir="ltr">Pergoveris contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, i.e. essentially &ldquo;sodium-free&rdquo;.</p><p dir="ltr">&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Always use this medicine<strong> </strong>exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Using this medicine</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pergoveris is intended to be given by injection just under the skin (subcutaneously). To minimise skin irritation, select a different injection site each day.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor or nurse will show you how to use the Pergoveris pre-filled pen to inject the medicine.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If they are satisfied that you can administer Pergoveris safely, you can then prepare and inject the medicine yourself at home.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you administer Pergoveris to yourself, please carefully read and follow section &ldquo;Instructions for Use&rdquo;.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>How much to use</strong></p><p dir="ltr">A treatment regimen commences with the recommended dose of Pergoveris containing 150&nbsp;International Units (IU) of follitropin alfa and 75&nbsp;IU of lutropin alfa every day.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; According to your response, your doctor may decide to add every day a dose of a licensed follitropin alfa preparation to your Pergoveris injection. In this case, the follitropin alfa dose is usually increased every 7 or every 14&nbsp;days by 37.5 to 75&nbsp;IU.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment is continued until you get the desired response. This is when you have developed a suitable follicle, as assessed using ultrasound scans and blood tests.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This may take up to 5&nbsp;weeks.</p><p dir="ltr">&nbsp;</p><p dir="ltr">When you get the desired response, you will be given a single injection of human chorionic gonadotropin (hCG) 24 to 48&nbsp;hours after your last Pergoveris injection. The best time to have sex is on the day of the hCG injection and the day after. Alternatively, intrauterine insemination (IUI) may be performed.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If your body responds too strongly, your treatment will be stopped and you will not be given any hCG (see in section&nbsp;2. under &rdquo;Ovarian hyperstimulation syndrome (OHSS)&rdquo;). In this case, your doctor will give you a lower follitropin alfa dose in the following cycle.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>If you use more Pergoveris than you should</strong></p><p dir="ltr">The effects of an overdose of Pergoveris are unknown, nevertheless one could expect OHSS to occur. However this will only occur if hCG is administered (see in section&nbsp;2. under &ldquo;Ovarian hyperstimulation syndrome (OHSS)&rdquo;).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>If you forget to use Pergoveris</strong></p><p dir="ltr">Do not use a double dose to make up for a forgotten dose. Please contact your doctor.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr">If you have any further question on the use of this medicine, ask your doctor, pharmacist or nurse.</p><p dir="ltr">&nbsp;</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Most serious side effects</strong></p><p dir="ltr"><strong>Contact your doctor straight away if you notice any of the below listed side effects. The doctor might ask you to stop using Pergoveris.</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Allergic reactions</u></p><p dir="ltr">Allergic reactions such as rash, red skin, hives, swelling of your face with difficulty breathing can sometimes be serious. This side effect is very rare.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Ovarian hyperstimulation syndrome (OHSS)</u></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lower abdominal pain together with nausea or vomiting. These may be the symptoms of ovarian hyperstimulation syndrome (OHSS). Your ovaries may have over-reacted to the treatment and formed large sacs of fluid or cysts (see in section&nbsp;2. under &ldquo;Ovarian hyperstimulation syndrome (OHSS)&rdquo;). This side effect is common. If this happens, your doctor will need to examine you as soon as possible.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The OHSS may become severe with clearly enlarged ovaries, decreased urine production, weight gain, difficulty in breathing and/or possible fluid accumulation in your stomach or chest. This side effect is uncommon (may affect up to 1 in 100&nbsp;people).</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complications of OHSS such as twisting of ovaries or blood clotting occur rarely (may affect up to 1 in 1,000 people).</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious blood clotting problems (thromboembolic events) usually with severe OHSS are found very rarely. This could cause chest pain, breathlessness, stroke or heart attack. In rare cases this can also happen independently of OHSS (see in section&nbsp;2. under &ldquo;Blood clotting problems (thromboembolic events)&rdquo;).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Other side effects</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Very common</u> (may affect more than 1 in 10&nbsp;people):</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sacs of fluid within the ovaries (ovarian cysts)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; local reactions at the injection site such as pain, itching, bruising, swelling or irritation.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Common</u> (may affect up to 1 in 10&nbsp;people):</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breast pain</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick or vomiting</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal or pelvic pain</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal cramp or bloating.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Very rare</u> (may affect up to 1 in 10,000&nbsp;people):</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your asthma may get worse.</p><p dir="ltr">&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Keep this medicine out of the sight and reach of children.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Do not use this medicine after the expiry date which is stated on the label and the carton after EXP. The expiry date refers to the last day of that month.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Store in a refrigerator (2&deg;C-8&deg;C). Do not freeze.</p><p dir="ltr">Store in the original package in order to protect from light.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Once opened, the pre-filled pen may be stored for a maximum of 28 days outside of the refrigerator (at 30&deg;C).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Do not use Pergoveris if you notice any visible signs of deterioration, if the liquid contains particles or is not clear.</p><p dir="ltr">&nbsp;</p><p dir="ltr">After the injection, dispose of the used needle safely.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Pergoveris contains</strong></p><p dir="ltr">The active substances are follitropin alfa and lutropin alfa.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each pre-filled pen of Pergoveris (450&nbsp;IU + 225&nbsp;IU)/0.72&nbsp;mL contains 450 IU (International Units) of follitropin alfa and 225&nbsp;IU of lutropin alfa in 0.72&nbsp;mL and can deliver three doses of Pergoveris 150&nbsp;IU/75&nbsp;IU.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The other ingredients are</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sucrose, arginine monohydrochloride, poloxamer&nbsp;188, methionine, phenol, disodium phosphate dihydrate, sodium dihydrogen phosphate monohydrate and water for injections. Tiny amounts of concentrated phosphoric acid and sodium hydroxide are added to keep acidity levels (pH levels) normal.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Pergoveris looks like and contents of the pack
Pergoveris is presented as a clear, colourless to slightly yellow solution for injection in a mulitidose pre filled pen: 
•	Pergoveris (450 IU + 225 IU)/0.72 mL is supplied in packs of 1 multidose pre-filled pen and 7 disposable injection needles. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Marketing Authorisation Holder</strong></p><p dir="ltr">Merck Europe B.V.,</p><p dir="ltr">Gustav Mahlerplein 102,</p><p dir="ltr">1082 MA Amsterdam, The Netherlands</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Manufacturer</strong></p><p dir="ltr">Merck Serono S.p.A,</p><p dir="ltr">Via delle Magnolie 15 (Zona industriale),</p><p dir="ltr">I-70026 Modugno (Bari), Italy</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in {April/2020}.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو بيرغوفيريس</strong></p><p dir="RTL">يحتوي بيرغوفيريس على مادتين فعالتين مختلفتين تدعيان &quot;فوليتروبين ألفا&quot; و&quot;لوتروبين ألفا&quot;.<strong> </strong>ينتمي كلاهما إلى عائلة هرمونات تسمى &quot;منشطات الغدد التناسلية&quot; والتي لها دور في الإنجاب والخصوبة.</p><p>&nbsp;</p><p dir="RTL"><strong>ما دواعي استعمال بيرغوفيريس</strong></p><p dir="RTL">يُستعمَل هذا الدواء لتحفيز نمو الجُرَيبات (والتي يحتوي كلٌ منها على بويضة) في مبيضيكِ. يساعدك هذا الأمر على الحمل. وهو مخصص للاستعمال لدى النساء البالغات (ابتداءً من عمر 18&nbsp;عاماً) واللاتي يعانين تدني مستويات &quot;الهرمون المنشط للجُرَيبات&quot; و&quot;الهرمون المنشط للجسم الأصفر&quot;. عادةً ما تكون هذه النساء عقيمات.</p><p>&nbsp;</p><p dir="RTL"><strong>كيفية عمل بيرغوفيريس</strong></p><p dir="RTL">المادتين الفعالتين في بيرغوفيريس هما نسختان عن الهرمون المنشط للجُرَيبات والهرمون المنشط للجسم الأصفر الطبيعيين. في جسمك:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفّز الهرمون المنشط للجُرَيبات لإنتاج البويضات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفّز الهرمون المنشط للجسم الأصفر لإطلاق هذه البويضات.</p><p>&nbsp;</p><p dir="RTL">من خلال استبدال الهرمونات المفقودة، يسمح بيرغوفيريس بأن ينمو لدى النساء اللاتي يعانين تدني مستويات الهرمون المنشط للجُرَيبات والهرمون المنشط للجسم الأصفر جُرَيبة. سيُطلِق هذا الأمر عندها بويضة، بعد حقنة هرمون &quot;منشط الغدد التناسلية المشيمي البشري&quot;. سيساعد هذا الأمر النساء على الحمل.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب تقييم حالة الخصوبة لديكِ ولدى زوجكِ قبل بدء العلاج تحت إشراف طبيب ذي خبرة في مجال علاج مشكلات الخصوبة.</p><p>&nbsp;</p><p dir="RTL"><strong>لا تستعملي بيرغوفيريس في الحالات التالية</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديكِ حساسية تجاه الهرمون المنشط للجُرَيبات، أو الهرمون المنشط للجسم الأصفر، أو أيّ مكونات أخرى يحتوي عليها هذا الدواء (الواردة في القسم&nbsp;6)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تعانين ورماً في المخ (في الوِطاء أو الغدة النخامية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تعانين من تضخم في المبيضين أو من ظهور أكياس في المبيض داخلها سائل (تكيس المبيض) مجهول المنشأ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تعانين من نزيف مهبلي غير مفسر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تعانين سرطاناً في المبيضين أو الرحم أو الثدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تعانين من حالة تجعل الحمل الطبيعي مستحيلاً، مثل انقطاع الطمث المبكر، أو تشوهات في الأعضاء التناسلية، أو الأورام الحميدة في الرحم.</p><p>&nbsp;</p><p dir="RTL">لا تستعملي هذا الدواء إذا كان أيّاً مما سبق ينطبق عليك. إذا لم تكوني متأكدة، فالرجاء التحدّث إلى الصيدلي أو الممرضة قبل استعمال هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">تحدّثي إلى طبيبك أو الصيدلي أو الممرضة قبل استعمال بيرغوفيريس.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong><u>البورفيريا</u></strong></p><p dir="RTL">تحدثي إلى طبيبك قبل البدء بتناول علاجك. إذا كنتِ أنتِ أو أيّاً من أفراد عائلتك مصابين بالبُرفيرية (عجز عن تجزئة البُرفيرين قد تنتقل من الآباء إلى أبنائهم).</p><p dir="RTL">أخبري طبيبك على الفور إذا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبح جلدك ضعيف وسريع التقرّح، خاصة الجلد الذي كان معرضًا لضوء الشمس بشكل متكرر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعرتِ بألم في المعدة أو الذراع أو الساق.</p><p>&nbsp;</p><p dir="RTL">في حال تعرّضتِ للآثار المذكورة أعلاه، قد ينصحكِ طبيبكِ بإيقاف العلاج.</p><p>&nbsp;</p><p dir="RTL"><strong><u>متلازمة فرط تحفيز المبيض</u></strong><strong><u>(OHSS)</u></strong></p><p dir="RTL">يحفّز هذا الدواء مبيضيكِ. فهذا يزيد من خطر إصابتك بمتلازمة فرط تحفيز المبيض (OHSS). يحدث هذا الأمر عندما تنمو الجُرَيبات بشكل كبير وتتحوّل إلى تكيّسات كبيرة. تحدثي إلى طبيبك على الفور إذا شعرتِ بألم في الجزء الأسفل من البطن أو زاد وزنك بسرعة أو شعرتِ بالغثيان أو تقيأتِ أو عانيتِ صعوبة في التنفس. فقد يطلب منكِ التوقف عن استعمال هذا الدواء (انظري القسم&nbsp;4، تحت عنوان &quot;أكثر الآثار الجانبية خطورة&quot;).</p><p>&nbsp;</p><p dir="RTL">&nbsp;تقل احتمالية حدوث متلازمة فرط تحفيز المبيض الشديدة في حالة عدم حدوث التبويض لديكِ وفي حالة الالتزام بالجرعة الموصى بها والجدول الزمني لاستخدام الدواء. نادراً ما يسبب العلاج بواسطة بيرغوفيريس متلازمة فرط تحفيز المبيض الشديدة. ولكن احتمالات الإصابة تزداد في حالة إعطاء الدواء المستخدم لتحفيز النضج النهائي للجريب (يحتوي على منشط الغدد التناسلية المشيمي البشري (hCG)) (انظري القسم&nbsp;3، تحت عنوان &quot;الكمية الواجب استعمالها&quot; للمزيد من التفاصيل). إذا كنت في طور الإصابة بمتلازمة فرط تحفيز المبيض، فقد يعطيكِ طبيبكِ أيّاً من منشطات الغدد التناسلية المشيمية البشرية في هذه الدورة العلاجية وقد يُطلَب منكِ عدم ممارسة الجماع أو استعمال وسيلة من وسائل منع الحمل الحاجزة لمدة أربعة أيام على الأقل.</p><p dir="RTL">سيضمن طبيبكِ مراقبةً دقيقة لاستجابة المبيضين بناءً على الموجات فوق الصوتية واختبارات الدم (قياسات الإستراديول) قبل مجرى العلاج وخلاله.</p><p>&nbsp;</p><p dir="RTL"><strong><u>الحمل المتعدد</u></strong></p><p dir="RTL">&nbsp;عند استعمال بيرغوفيريس، تزداد نسبة خطر حملك بأكثر من طفل في نفس الوقت (&quot;الحمل المتعدد&quot;، توائم غالبًا)، مقارنةً بما إذا حملتِ بشكل طبيعي. وقد يؤدي الحمل المتعدد إلى حدوث مضاعفات طبية لكِ ولأطفالك. بإمكانكِ الحدّ من خطر الحمل المتعدد من خلال استعمال الجرعة المناسبة من بيرغوفيريس في الأوقات المناسبة.</p><p>&nbsp;</p><p dir="RTL">للحدّ من خطر حدوث الحمل المتعدد، يوصى بإجراء فحوص المسح بالموجات فوق الصوتية وكذلك اختبارات الدم.</p><p>&nbsp;</p><p dir="RTL"><strong><u>الإِجهاض</u></strong></p><p dir="RTL">عند التعرض لتحفيز المبايض لديكِ لإنتاج البويضات، تكونين أكثر عُرضةً للإجهاض من المرأة العادية.</p><p>&nbsp;</p><p dir="RTL"><strong><u>الحمل خارج الرحم</u></strong></p><p dir="RTL">تتعرض النساء اللاتي كنّ مصابات في ما مضى بانسداد قنوات فالوب أو تلفها (مرض قنوات فالوب) لخطر الحمل حيث يتم زرع الجنين في خارج الرحم (حمل خارج الرحم). ويتم ذلك سواءٌ أكان الحمل عن طريق الإخصاب التلقائي أو من خلال علاجات الخصوبة.</p><p>&nbsp;</p><p dir="RTL"><strong><u>مشاكل تجلط الدم (حالات الانصمام الخثاري)</u></strong></p><p dir="RTL">تحدثي إلى طبيبكِ قبل استعمال بيرغوفيريس إذا كنتِ أنتِ أو أحد أفراد عائلتك قد تعرّضتم لجلطات دم في الساق أو الرئة أو لنوبة قلبية أو سكتة دماغية. قد تكوني معرّضة لخطر أكبر من الإصابة بجلطات دم أو قد تتفاقم الجلطات الموجودة لديكِ بسبب العلاج بواسطة بيرغوفيريس.</p><p><u>&nbsp;</u></p><p dir="RTL"><strong><u>أورام الأعضاء التناسلية</u></strong></p><p dir="RTL">وردت تقارير تفيد عن أورام حميدة وخبيثة على حدٍ سواء في المبيضين وغيرها من الأعضاء التناسلية لدى النساء اللاتي خضعن لأنظمة متعددة لعلاج العقم.</p><p><u>&nbsp;</u></p><p dir="RTL"><strong><u>تفاعلات الحساسية</u></strong></p><p dir="RTL">وردت تقارير منفصلة عن تفاعلات حساسية غير خطِرة لبيرغوفيريس. إذا كنتِ قد تعرّضتِ في ما مضى لهذا النوع من ردود الفعل على دواء مشابه، فتحدثي إلى طبيبك قبل استعمال بيرغوفيريس.</p><p>&nbsp;</p><p dir="RTL"><strong>الطفلات والمراهقات</strong></p><p dir="RTL">بيرغوفيريس غير مخصص للاستعمال لدى الأطفال والمراهقين ما دون 18 عاماً من العمر.</p><p>&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وبيرغوفيريس</strong></p><p dir="RTL">أخبري الطبيب أو الصيدلي إذا كنت تستعملين أيّ أدوية أخرى أو كنت قد استعملتيها مؤخرًا أو من المحتمل أن تستعمليها.</p><p>&nbsp;</p><p dir="RTL">لا تستعملي بيرغوفيريس مع أيّ أدوية أخرى في نفس الحقنة. بإمكانكِ استعمال بيرغوفيريس مع مستحضر فوليتروبين ألفا مرخّص كحقن منفصلة إذا وصف لكِ طبيبكِ ذلك.</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل والإرضاع</strong></p><p dir="RTL">لا تستخدمي بيرغوفيريس إذا كنتِ حاملاً أو مُرضعة.</p><p>&nbsp;</p><p dir="RTL"><strong>القيادة واستعمال الآلات</strong></p><p dir="RTL">من غير المتوقع أن يؤثر هذا الدواء على قدرتكِ على القيادة واستعمال الآلات.</p><p>&nbsp;</p><p dir="RTL"><strong>يحتوي بيرغوفيريس على الصوديوم</strong></p><p dir="RTL">يحتوي بيرغوفيريس على أقل من 1&nbsp;مللي مول من الصوديوم (23&nbsp;ملغ) في كل جرعة، أي إنه &quot;خالٍ من الصوديوم&quot; تقريباً.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">استعملي هذا الدواء دائماً<strong> </strong>حسب توجيهات طبيبكِ أو الصيدلي تماماً. يجب استشارة طبيبك أو الصيدلي إذا كنت غير متأكد.</p><p>&nbsp;</p><p dir="RTL"><strong>استعمال هذا الدواء</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بيرغوفيريس مخصص للحقن تحت الجلد فقط. للحدّ من تهيّج الجلد، اختاري موضع حقن مختلف كل يوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سوف يوضح لكِ طبيبكِ أو ممرضتكِ طريقة استعمال قلم بيرغوفيريس المعبأ مسبقاً لحقن الدواء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبحا راضيين عن قدرتكِ على حقن نفسكِ ببيرغوفيريس بشكل آمن، فسيكون بإمكانك تحضير الدواء وحقنه بنفسكِ في المنزل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تحقنين نفسكِ ببيرغوفيريس، فيُرجى قراءة قسم &quot;إرشادات الاستعمال&quot; بعناية واتّباعها بدقة.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الكمية الواجب استعمالها</strong></p><p dir="RTL">يبدأ نظام العلاج بالجرعة الموصى بها من بيرغوفيريس والتي تحتوي على 150 وحدة دولية من فوليتروبين ألفا و75 وحدة دولية من لوتروبين ألفا يومياً.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يقرر طبيبكِ، بناءً على استجابتكِ للدواء، إضافة جرعة من أحد مستحضرات فوليتروبين ألفا المرخّصة إلى حقنة بيرغوفيريس. في هذه الحال، تتم عادةً زيادة جرعة فوليتروبين ألفا كل 7&nbsp;أيام أو كل 14&nbsp;يوماً بمعدل يتراوح ما بين 37,5&nbsp;و75&nbsp;وحدة دولية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتم مواصلة العلاج حتى حصولكِ على الاستجابة المرجوّة. ويكون ذلك عندما ينمو لديك جُرَيب مناسب، بحسب تقييمات مسوح الموجات فوق الصوتية واختبارات الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يستغرق ذلك حتى 5 أسابيع.</p><p>&nbsp;</p><p dir="RTL">عندما تحصلين على الاستجابة المرجوّة، سيتم إعطاؤكِ جرعة واحدة من منشط الغدد التناسلية المشيمي البشري بعد مرور 24&nbsp;إلى 48&nbsp;ساعةً على جرعة بيرغوفيريس الأخيرة. يكون أفضل وقت لممارسة الجماع في يوم حقنة منشط الغدد التناسلية المشيمي البشري واليوم التالي له. أو بدلاً من ذلك، يمكن إجراء تلقيح داخل الرحم.</p><p>&nbsp;</p><p dir="RTL">إذا كانت استجابة جسمك قوية للغاية، فسيتم إيقاف علاجكِ ولن يتم إعطاؤكِ أيّ نوع من منشط الغدد التناسلية المشيمي البشري (انظري القسم&nbsp;2، تحت عنوان &quot;متلازمة فرط تحفيز المبيض (OHSS)&quot;). في هذه الحال، سيعطيكِ طبيبكِ جرعة أدنى من فوليتروبين ألفا في الدورة التالية.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا استعملتِ كمية من بيرغوفيريس أكبر مما يجب</strong></p><p dir="RTL">آثار الجرعة الزائدة من بيرغوفيريس غير معلومة، إلّا أننا نتوقع حدوث متلازمة فرط تحفيز المبيض. ولكل ذلك لن يحدث سوى في حال إعطاء منشط الغدد التناسلية المشيمي البشري (انظري القسم&nbsp;2، تحت عنوان &quot;متلازمة فرط تحفيز المبيض (OHSS)&quot;).</p><p>&nbsp;</p><p dir="RTL"><strong>إذا نسيتِ استعمال بيرغوفيريس</strong></p><p dir="RTL">يُحظر تناول جرعة مضاعفة لتعويض الجرعة التي نسيتها. الرجاء الاتصال بطبيبكِ.</p><p><strong>&nbsp;</strong></p><p dir="RTL">إذا راودتكِ أيّ أسئلة إضافية حول استعمال هذا الدواء، فاطرحيها على طبيبك أو الصيدلي أو الممرضة.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شأنه شأن كل الأدوية، يسبب هذا الدواء آثاراً جانبية على الرغم من أنها لا تصيب جميع من يتناوله.</p><p>&nbsp;</p><p dir="RTL"><strong>أكثر الآثار الجانبية خطورة</strong></p><p dir="RTL"><strong>اتصلي بطبيبكِ على الفور إذا لاحظتِ أيّاً من الآثار الجانبية الواردة أدناه.</strong><strong> </strong><strong>قد يطلب إليكِ طبيبكِ إيقاف استعمال بيرغوفيريس.</strong></p><p>&nbsp;</p><p dir="RTL"><strong><u>تفاعلات الحساسية</u></strong></p><p dir="RTL">قد تكون تفاعلات الحساسية مثل الطفح الجلدي، واحمرار الجلد، والشَرَى، وتورّم وجهك المصحوب بصعوبة في التنفس خطِرة أحياناً. هذا الأثر الجانبي نادر جداً.</p><p>&nbsp;</p><p dir="RTL"><strong><u>متلازمة فرط تحفيز المبيض</u></strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الجهة السفلية من البطن والمصحوب بالغثيان أو القيء. قد تكون هذه من أعراض متلازمة فرط تحفيز المبيض. قد يكون مبيضاكِ استجابا استجابة مفرطة للعلاج وكوّنا أكياساً كبيرة من السائل أو تكيّسات (انظري أيضًا القسم&nbsp;2 تحت عنوان &quot;متلازمة فرط تحفيز المبيض (OHSS)&quot;). هذا الأثر الجانبي شائع. في حال حدوث ذلك، سيكون على طبيبكِ فحصكِ في أقرب مهلة ممكنة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تصبح متلازمة فرط تحفيز المبيض شديدة ويصحبها تضخّم واضح في المبيضين، وتدني إفراز البول، وزيادة الوزن، والصعوبة في التنفس، و/أو إمكان تراكم السوائل في المعدة أو الصدر. هذا الأثر الجانبي غير شائع (قد يصيب 1&nbsp;من بين كل 100&nbsp;شخص).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نادراً ما تحدث مضاعفات متلازمة فرط تحفيز المبيض مثل التواء المبيضين أو تجلّط الدم (قد تصيب حتى 1 من كل 1000 شخص).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عادةً ما تكون مشكلات تجلّط الدم الخطِرة (حالات الانصمام الخثاري) نادرة جداً مع متلازمة فرط تحفيز المبيض الشديد. قد يسبب ذلك ألم في الصدر أو ضيقاً في التنفس أو سكتة دماغية أو نوبة قلبية. في حالاتٍ نادرة، قد يحدث ذلك أيضاً بغضّ النظر عن متلازمة فرط تحفيز المبيض (انظري القسم&nbsp;2. تحت عنوان &quot;مشاكل تجلّط الدم (حالات الانصمام الخثاري)&quot;).</p><p>&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الأخرى</strong></p><p>&nbsp;</p><p dir="RTL"><strong><u>الآثار الجانبية الشائعة جداً </u></strong><strong>(قد تصيب أكثر من </strong><strong>1</strong><strong>&nbsp;من كل </strong><strong>10</strong><strong>&nbsp;أشخاص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أكياس السائل في داخل المبيضين (تكيّس المبيضين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود الفعل الموضعية في موضع الحقن؛ مثل الألم أو الحكة أو الكدمات أو التورّم أو التهيج.</p><p>&nbsp;</p><p dir="RTL"><strong><u>الشائعة </u></strong><strong>(قد تصيب حتى </strong><strong>1</strong><strong>&nbsp;من بين كل </strong><strong>10</strong><strong>&nbsp;أشخاص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالغثيان أو القيء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في البطن أو الحوض</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنّجات البطن أو الانتفاخ.</p><p>&nbsp;</p><p dir="RTL"><strong><u>النادرة جداً</u></strong><strong> (قد تصيب حتى </strong><strong>1</strong><strong>&nbsp;من بين كل </strong><strong>10,000</strong><strong>&nbsp;شخص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تتفاقم حالة الربو لديكِ.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفَظ هذا الدواء بعيداً عن مرأى الأطفال ومتناول أيديهم.</p><p>&nbsp;</p><p dir="RTL">لا تستعملي هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على الملصق والعلبة بعد كلمة EXP. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر المذكور.</p><p>&nbsp;</p><p dir="RTL">يحفظ في الثلاجة (من 2&nbsp;إلى 8&nbsp;درجات مئوية). ولكن لا تحفظيه بالتجميد.</p><p dir="RTL">يخزن داخل العبوة الأصلية للحماية من الضوء.</p><p>&nbsp;</p><p dir="RTL">بعد فتح القلم المعبأ مسبقاً، يمكن تخزينه خارج الثلاجة لمدة 28&nbsp;يوماً كحد أقصى (في درجة حرارة 30 مئوية).</p><p>&nbsp;</p><p dir="RTL">لا تستعملي بيرغوفيريس إذا لاحظتِ أيّ مؤشرات تدلّ على تلفه أو إذا كان السائل يحتوي على جزيئات أو غير شفاف.</p><p>&nbsp;</p><p dir="RTL">بعد الحقن، تخلصي من الإبرة المستعمَلة بشكل آمن.</p><p>&nbsp;</p><p dir="RTL">لا تتخلصي من أيّ أدوية في مياه الصرف أو النفايات المنزلية. اسألي الصيدلي عن طريقة التخلص من الأدوية التي لم تعد تستخدمها، لأن اتباع هذه الطريقة يساعد على حماية البيئة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هي محتويات بيرغوفيريس</strong></p><p dir="RTL">المادة الفعّالة هي فوليتروبين ألفا ولوتروبين ألفا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحتوي كل قلم معبأ مسبقاً من بيرغوفيريس (450&nbsp;وحدة دولية + 225&nbsp;وحدة دولية)/0,72&nbsp;مل على 450&nbsp;وحدة دولية من فوليتروبين ألفا و225&nbsp;وحدة دولية من لوتروبين ألفا في 0,72&nbsp;مل وبإمكانه حقن ثلاث جرعاتٍ من بيرغوفيريس 150&nbsp;وحدة دولية/75&nbsp;وحدة دولية.</p><p>&nbsp;</p><p dir="RTL">المكونات الأخرى هي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سُكروز، أحادي هيدروكلوريد الأرجينين، بولوكسامير 188، ميثيونين، فينول، فوسفات الصوديوم ثنائي الهيدرات، فوسفات ثاني هيدروجين الصوديوم أحادي الهيدرات، وماء للحقن. كميات ضئيلة من حمض الفوسفوريك وهيدروكسيد الصوديوم المُركّزين لإبقاء مستويات الحموضة طبيعية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شكل بيرغوفيريس ومحتويات العلبة</strong></p><p dir="RTL">يأتي بيرغوفيريس في شكل محلول شفاف، لا لون له إلى مائل إلى الصفار للحقن في قلم معبأ مسبقاً متعدد الجرعات:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يأتي بيرغوفيريس (450&nbsp;وحدة دولية + 225&nbsp;وحدة دولية)/0,72&nbsp;مل في علب تحتوي على قلم معبأ مسبقاً متعدد الجرعات واحد و7 إبر حقن تستعمل لمرة واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك حق التسويق</strong></p><p>میرك أوروبا بي في</p><p>غوستاف ماھلر، 102</p><p>أمستردا م MA 1082</p><p dir="RTL">ھولندا</p><p>&nbsp;</p><p dir="RTL"><strong>الشركة المصنعه </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">شركة ميرك سيرونو،</p><p dir="RTL">&nbsp;شركة مساهمة،</p><p dir="RTL">&nbsp;15 شارع ماجنولي،</p><p dir="RTL">&nbsp;أي-70026 مودوجنو (باري)،</p><p dir="RTL">&nbsp;إيطاليا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة لهذه النشرة في ابريل /2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pergoveris (450 IU + 225 IU)/0.72 mL solution for injection in pre-filled pen
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each multidose pre-filled pen contains 450 IU (equivalent to 33 micrograms) of follitropin alfa* (r hFSH) and 225 IU (equivalent to 9 micrograms) of lutropin alfa* (r hLH) in 0.72 mL solution.

*recombinant human follitropin alfa and recombinant human lutropin alfa are produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection (injection).
Clear, colorless to slightly yellow solution.

The pH of the solution is 6.5 – 7.5, its osmolality is 250 – 400 mOsm/kg.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pergoveris is indicated for the stimulation of follicular development in adult women with severe LH and FSH deficiency.</p><p dir="ltr">In clinical trials, these patients were defined by an endogenous serum LH level &lt;&nbsp;1.2&nbsp;IU/L.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Treatment with Pergoveris should be initiated under the supervision of a physician experienced in the treatment of fertility problems.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Posology</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">In LH and FSH deficient women (hypogonadotrophic hypogonadism), the objective of Pergoveris therapy is to develop a single mature Graafian follicle from which the oocyte will be liberated after the administration of human chorionic gonadotrophin (hCG). Pergoveris should be given as a course of daily injections. Since these patients are amenorrhoeic and have low endogenous oestrogen secretion, treatment can commence at any time.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Treatment should be tailored to the individual patient&rsquo;s response as assessed by measuring follicle size by ultrasound and oestrogen response.</p><p dir="ltr">&nbsp;</p><p dir="ltr">A treatment regimen commences with the recommended dose of Pergoveris containing 150&nbsp;IU r‑hFSH/75&nbsp;IU r‑hLH daily. If less than the recommended dose daily is used, the follicular response may be unsatisfactory because the amount of lutropin alfa may be insufficient (see section&nbsp;5.1).</p><p dir="ltr">&nbsp;</p><p dir="ltr">If an FSH dose increase is deemed appropriate, dose adaptation should preferably be after 7-14&nbsp;day intervals and preferably by 37.5-75&nbsp;IU increments using a licensed follitropin alfa preparation. It may be acceptable to extend the duration of stimulation in any one cycle to up to 5&nbsp;weeks.</p><p dir="ltr">&nbsp;</p><p dir="ltr">When an optimal response is obtained, a single injection of 250&nbsp;micrograms of r-hCG or 5,000&nbsp;IU to 10,000&nbsp;IU hCG should be administered 24-48&nbsp;hours after the last Pergoveris injection. The patient is recommended to have coitus on the day of, and on the day following, hCG administration. Alternatively, intrauterine insemination (IUI) may be performed.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Luteal phase support may be considered since lack of substances with luteotrophic activity (LH/hCG) after ovulation may lead to premature failure of the corpus luteum.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If an excessive response is obtained, treatment should be stopped and hCG withheld. Treatment should recommence in the next cycle at a dose of FSH lower than that of the previous cycle.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Special populations</u></em></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><em>Elderly</em></p><p dir="ltr">There is no relevant indication for the use of Pergoveris in the elderly population. Safety and effectiveness of this medicinal product in elderly patients have not been established.</p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr"><em>Renal and hepatic impairment</em></p><p dir="ltr">Safety, efficacy, and pharmacokinetics of this medicinal product in patients with renal or hepatic impairment have not been established.</p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr"><em>Paediatric population</em></p><p dir="ltr">There is no relevant use of this medicinal product in the paediatric population.</p><p dir="ltr"><em><u>&nbsp;</u></em></p><p dir="ltr"><u>Method of administration</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">Pergoveris is intended for subcutaneous administration. The first injection should be performed under direct medical supervision. Self-administration should only be performed by patients who are well motivated, adequately trained and with access to expert advice.</p><p dir="ltr">&nbsp;</p><p dir="ltr">For instructions on the use of this medicinal product, see section&nbsp;6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pergoveris is contraindicated in patients with:
•	hypersensitivity to the active substances or to any of the excipients listed in section 6.1
•	tumours of the hypothalamus and pituitary gland
•	ovarian enlargement or ovarian cyst unrelated to polycystic ovarian disease and of unknown origin
•	gynaecological haemorrhages of unknown origin
•	ovarian, uterine or mammary carcinoma

Pergoveris must not be used when an effective response cannot be obtained, such as:
•	primary ovarian failure
•	malformations of sexual organs incompatible with pregnancy
•	fibroid tumours of the uterus incompatible with pregnancy

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pergoveris contains potent gonadotrophic substances capable of causing mild to severe adverse reactions, and should only be used by physicians who are thoroughly familiar with infertility problems and their management.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Gonadotrophin therapy requires a certain time commitment by physicians and supportive health care professionals, as well as the availability of appropriate monitoring facilities. In women, safe and effective use of Pergoveris calls for monitoring of ovarian response with ultrasound, alone or preferably in combination with measurement of serum oestradiol levels, on a regular basis. There may be a degree of interpatient variability in response to FSH/LH administration, with a poor response to FSH/LH in some patients. The lowest effective dose in relation to the treatment objective should be used in women.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Porphyria</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">Patients with porphyria or a family history of porphyria should be closely monitored during treatment with Pergoveris. In these patients, Pergoveris may increase the risk of an acute attack. Deterioration or a first appearance of this condition may require cessation of treatment.</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><u>Treatment in women</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">Before starting treatment, the couple&#39;s infertility should be assessed as appropriate and putative contraindications for pregnancy evaluated. In particular, patients should be evaluated for hypothyroidism, adrenocortical deficiency, hyperprolactinemia and appropriate specific treatment should be given.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Patients undergoing stimulation of follicular growth are at an increased risk of developing hyperstimulation in view of possible excessive oestrogen response and multiple follicular development.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Ovarian hyperstimulation syndrome (OHSS)</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">A certain degree of ovarian enlargement is an expected effect of controlled ovarian stimulation. It is more commonly seen in women with polycystic ovarian syndrome and usually regresses without treatment.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In distinction to uncomplicated ovarian enlargement, OHSS is a condition that can manifest itself with increasing degrees of severity. It comprises marked ovarian enlargement, high serum sex steroids, and an increase in vascular permeability which can result in an accumulation of fluid in the peritoneal, pleural and, rarely, in the pericardial cavities.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The following symptomatology may be observed in severe cases of OHSS: abdominal pain, abdominal distension, severe ovarian enlargement, weight gain, dyspnoea, oliguria and gastrointestinal symptoms including nausea, vomiting and diarrhoea.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Clinical evaluation may reveal hypovolaemia, haemoconcentration, electrolyte imbalances, ascites, haemoperitoneum, pleural effusions, hydrothorax, or acute pulmonary distress, and thromboembolic events.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Very rarely, severe OHSS may be complicated by ovarian torsion or thromboembolic events such as pulmonary embolism, ischaemic stroke or myocardial infarction.</p><p dir="ltr">Independent risk factors for developing OHSS include young age, lean body mass, polycystic ovarian syndrome, higher doses of exogenous gonadotrophins, high absolute or rapidly rising serum oestradiol level (&gt;&nbsp;900&nbsp;pg/mL or &gt;&nbsp;3,300&nbsp;pmol/L in anovulation), previous episodes of OHSS and large number of developing ovarian follicles (3&nbsp;follicles of &ge;&nbsp;14&nbsp;mm in diameter in anovulation).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Adherence to recommended Pergoveris and FSH dosage and regimen of administration can minimise the risk of ovarian hyperstimulation. Monitoring of stimulation cycles by ultrasound scans as well as oestradiol measurements are recommended to early identify risk factors.</p><p dir="ltr">&nbsp;</p><p dir="ltr">There is evidence to suggest that hCG plays a key role in triggering OHSS and that the syndrome may be more severe and more protracted if pregnancy occurs. Therefore, if signs of OHSS occur such as serum oestradiol level &gt;&nbsp;5,500&nbsp;pg/mL or &gt;&nbsp;20,200&nbsp;pmol/L and/or &ge;&nbsp;40&nbsp;follicles in total, it is recommended that hCG be withheld and the patient be advised to refrain from coitus or to use barrier contraceptive methods for at least 4&nbsp;days. OHSS may progress rapidly (within 24&nbsp;hours) or over several days to become a serious medical event. It most often occurs after hormonal treatment has been discontinued and reaches its maximum at about seven to ten days following treatment. Usually, OHSS resolves spontaneously with the onset of menses. Therefore patients should be followed for at least two weeks after hCG administration.</p><p dir="ltr">If severe OHSS occurs, gonadotropin treatment should be stopped if still ongoing. The patient should be hospitalised and specific therapy for OHSS started. This syndrome occurs with higher incidence in patients with polycystic ovarian disease.</p><p dir="ltr">&nbsp;</p><p dir="ltr">When a risk of OHSS is assumed, treatment discontinuation should be considered.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Ovarian torsion</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">Ovarian torsion has been reported after treatment with other gonadotropins. This may be associated with other risk factors such as OHSS, pregnancy, previous abdominal surgery, past history of ovarian torsion, previous or current ovarian cyst and polycystic ovarian syndrome. Damage to the ovary due to reduced blood supply can be limited by early diagnosis and immediate detorsion.</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><u>Multiple pregnancy</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">In patients undergoing induction of ovulation, the incidence of multiple pregnancies and births is increased compared with natural conception. The majority of multiple conceptions are twins. Multiple pregnancy, especially high order, carry an increased risk of adverse maternal and perinatal outcomes. To minimise the risk of multiple pregnancy, careful monitoring of ovarian response is recommended.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The patients should be advised of the potential risk of multiple births before starting treatment. When risk of multiple pregnancies is assumed, treatment discontinuation should be considered.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Pregnancy loss</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">The incidence of pregnancy loss by miscarriage or abortion is higher in patients undergoing stimulation of follicular growth for ovulation induction than in the normal population.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Ectopic pregnancy</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">Women with a history of tubal disease are at risk of ectopic pregnancy, whether the pregnancy is obtained by spontaneous conception or with fertility treatments. The prevalence of ectopic pregnancy after assisted reproductive technologies (ART) was reported to be higher than in the general population.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Reproductive system neoplasms</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">There have been reports of ovarian and other reproductive system neoplasms, both benign and malignant, in women who have undergone multiple regimens for infertility treatment. It is not yet established whether or not treatment with gonadotropins increases the risk of these tumours in infertile women.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><u>Congenital malformation</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">The prevalence of congenital malformations after ART may be slightly higher than after spontaneous conceptions. This is thought to be due to differences in parental characteristics (e.g. maternal age, sperm characteristics) and multiple pregnancies.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Thromboembolic events</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">In women with recent or ongoing thromboembolic disease or women with generally recognised risk factors for thromboembolic events, such as personal or family history, thrombophilia or severe obesity (body mass index &gt;&nbsp;30&nbsp;kg/m<sup>2</sup>), treatment with gonadotrophins may further increase the risk. In these women, the benefits of gonadotrophin administration need to be weighed against the risks. It should be noted however, that pregnancy itself as well as OHSS also carries an increased risk of thromboembolic events.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Sodium</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">Pergoveris contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, i.e. essentially &ldquo;sodium-free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pergoveris solution for injection in pre-filled pen must not be administered as a mixture with other medicinal products in the same injection.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Pergoveris solution for injection in pre-filled pen may be administered concomitantly with a licensed follitropin alfa preparation as separate injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Pregnancy</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">There is no indication for the use of Pergoveris during pregnancy. Data on a limited number of exposed pregnancies indicate no adverse reactions of follitropin alfa and lutropin alfa on pregnancy, embryonal or foetal development, parturition or postnatal development following controlled ovarian stimulation. No teratogenic effect of such gonadotropins has been reported in animal studies. In case of exposure during pregnancy, clinical data are not sufficient to exclude a teratogenic effect of Pergoveris.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Breast‑feeding</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">Pergoveris is not indicated during breast‑feeding.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Fertility</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">Pergoveris is indicated for use in infertility (see section&nbsp;4.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pergoveris has no or negligible influence on the ability to drive and use machines</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Summary of the safety profile</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">The most commonly reported adverse reactions are headache, ovarian cysts and local injection site reactions (e.g. pain, erythema, haematoma, swelling and/or irritation at the site of injection).</p><p dir="ltr">Mild or moderate OHSS has been commonly reported and should be considered as an intrinsic risk of the stimulation procedure. Severe OHSS is uncommon (see section&nbsp;4.4).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Thromboembolism may occur very rarely, usually associated with severe OHSS (see section&nbsp;4.4).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Tabulated list of adverse reactions</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Adverse reactions are listed below by MedDRA system organ class and by frequency. The frequency categories used are: very common (&ge;1/10), common (&sup3;1/100 to &lt;1/10), uncommon (&sup3;1/1,000 to &lt;1/100), rare (&sup3;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Immune system disorders</u></em></p><p dir="ltr">Very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mild to severe hypersensitivity reactions including anaphylactic reactions and shock</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><em><u>Nervous system disorders</u></em></p><p dir="ltr">Very common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><em><u>Vascular disorders</u></em></p><p dir="ltr">Very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thromboembolism, usually associated with severe OHSS</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Respiratory, thoracic and mediastinal disorders</u></em></p><p dir="ltr">Very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exacerbation or aggravation of asthma</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Gastrointestinal disorders</u></em></p><p dir="ltr">Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal pain, abdominal distension, abdominal discomfort, nausea, vomiting, diarrhoea</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><em><u>Reproductive system and breast disorders</u></em></p><p dir="ltr">Very common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ovarian cysts</p><p dir="ltr">Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breast pain, pelvic pain, mild or moderate OHSS (including associated symptomatology)</p><p dir="ltr">Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe OHSS (including associated symptomatology) (see section&nbsp;4.4)</p><p dir="ltr">Rare: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complication of severe OHSS</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><em><u>General disorders and administration site conditions</u></em></p><p dir="ltr">Very common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mild to severe injection site reactions (e.g. pain, erythema, haematoma, bruising, swelling and/or irritation at the site of injection)</p><p dir="ltr">&nbsp;</p><p dir="ltr">To report any side effect(s):</p><ul dir="ltr"><li><strong><em>Saudi Arabia: </em></strong></li></ul><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>- The National Pharmacovigilance Centre (NPC)</p><ul><li>Fax: +966-11-205-7662</li><li>Toll free phone: 8002490000</li><li>E-mail: npc.drug@sfda.gov.sa &nbsp;</li><li>Website: https://ade.sfda.gov.sa/</li></ul><p>&nbsp;</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p dir="ltr">&nbsp;</p><p dir="ltr">Please contact the relevant</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Symptoms</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">The effects of an overdose of Pergoveris are unknown. Nevertheless there is a possibility that OHSS may occur, which is further described in section&nbsp;4.4.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Management</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">Treatment is directed to symptoms.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pharmacotherapeutic group: Sex hormones and modulators of the genital system, gonadotropins. ATC code: G03GA30.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Pergoveris is a preparation of recombinant human follicle stimulating hormone (follitropin alfa, r‑hFSH) and recombinant human luteinising hormone (lutropin alfa, r-hLH) produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Mechanism of action</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">In clinical trials the efficacy of the combination of follitropin alfa and lutropin alfa has been demonstrated in women with hypogonadotropic hypogonadism.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In the stimulation of follicular development in anovulatory women deficient in LH and FSH, the primary effect resulting from administration of lutropin alfa is an increase in oestradiol secretion by the follicles, the growth of which is stimulated by FSH.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Pharmacodynamic effects</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">In clinical trials, patients with severe FSH and LH deficiency were defined by an endogenous serum LH level &lt;&nbsp;1.2&nbsp;IU/L as measured in a central laboratory. However, it should be taken into account that there are variations between LH measurements performed in different laboratories. In these trials the ovulation rate per cycle was 70-75%.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Clinical efficacy </u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">In one clinical study of women with hypogonadotrophic hypogonadism and an endogenous serum LH concentration below 1.2&nbsp;IU/L the appropriate dose of r-hLH was investigated. A dose of 75&nbsp;IU r-hLH daily (in combination with 150&nbsp;IU r-hFSH) resulted in adequate follicular development and oestrogen production. A dose of 25&nbsp;IU r-hLH daily (in combination with 150&nbsp;IU r-hFSH) resulted in insufficient follicular development.</p><p dir="ltr">Therefore, administration of Pergoveris containing less than 75&nbsp;IU r‑hLH daily may provide too little LH-activity to ensure adequate follicular development.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Follitropin alfa and lutropin alfa have shown the same pharmacokinetic profile as follitropin alfa and lutropin alfa separately.</p><p dir="ltr"><strong><em>&nbsp;</em></strong></p><p dir="ltr"><u>Follitropin alfa</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><em><u>Distribution</u></em></p><p dir="ltr">Following intravenous administration, follitropin alfa is distributed to the extracellular fluid space with an initial half-life of around 2&nbsp;hours and eliminated from the body with a terminal half-life of about one day. The steady state volume of distribution is 10&nbsp;L.</p><p dir="ltr">Following subcutaneous administration, the absolute bioavailability is about 70%. Following repeated administration, follitropin alfa accumulates 3‑fold achieving a<strong><em> </em></strong>steady‑state within 3-4&nbsp;days. In women whose endogenous gonadotrophin secretion is suppressed, follitropin alfa has nevertheless been shown to effectively stimulate follicular development and steroidogenesis, despite unmeasurable LH levels.</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><em><u>Elimination</u></em></p><p dir="ltr">Total clearance is 0.6&nbsp;L/h and one-eighth of the follitropin alfa dose is excreted in the urine.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Lutropin alfa</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><em><u>Distribution</u></em></p><p dir="ltr">Following intravenous administration, lutropin alfa is rapidly distributed with an initial half-life of approximately one hour and eliminated from the body with a terminal half-life of about 10-12&nbsp;hours. The steady state volume of distribution is around 10-14&nbsp;L. Lutropin alfa shows linear pharmacokinetics, as assessed by AUC which is directly proportional to the dose administered.</p><p dir="ltr">Following subcutaneous administration, the absolute bioavailability is approximately 60%; the terminal half-life is slightly prolonged. The lutropin alfa pharmacokinetics following single and repeated administration of lutropin alfa are comparable and the accumulation ratio of lutropin alfa is minimal. The mean residence time is approximately 5&nbsp;hours.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Elimination</u></em></p><p dir="ltr">Total clearance is around 2&nbsp;L/h, and less than 5% of the dose is excreted in the urine.</p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr"><em><u>Pharmacokinetic/pharmacodynamic relationships</u></em></p><p dir="ltr">There is no pharmacokinetic interaction with follitropin alfa when administered simultaneously.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Clinical studies with Pergoveris were conducted with a freeze-dried formulation. A comparative clinical study between the freeze-dried and the liquid formulation showed bioequivalence between the two formulations.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sucrose 27.7 iu</p><p dir="ltr">Arginine monohydrochloride 8.53 iu</p><p dir="ltr">Poloxamer 188 ( 0.18 iu )</p><p dir="ltr">Methionine 0.108 iu</p><p dir="ltr">Phenol 3.6 iu</p><p dir="ltr">Disodium phosphate dihydrate 0.81 iu</p><p dir="ltr">Sodium dihydrogen phosphate monohydrate 0.33 iu</p><p dir="ltr">Sodium hydroxide (for pH adjustment) Q.S</p><p dir="ltr">Phosphoric acid, concentrated (for pH adjustment) Q.S</p><p dir="ltr">Water for injections Q.S</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.

Chemical and physical in-use stability has been demonstrated for 28 days at 30°C.
Once opened, the product may be stored for a maximum of 28 days at 30°C. Other in-use storage times and conditions are the responsibility of the user.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Store in refrigerator (2&deg;C- 8&deg;C). Do not freeze.</p><p dir="ltr">Store in the original package in order to protect from light.</p><p dir="ltr">&nbsp;</p><p dir="ltr">For in-use storage conditions, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Colourless 3 mL glass cartridge (type I borosilicate glass, with a grey bromobutyl rubber plunger stopper and a crimp cap made with grey rubber stopper septum and aluminium) pre-assembled in a pre-filled pen.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Each Pergoveris (450&nbsp;IU + 225&nbsp;IU)/0.72&nbsp;mL pre-filled pen contains 0.72&nbsp;mL of solution for injection and can deliver three doses of Pergoveris 150&nbsp;IU/75&nbsp;IU.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Pack of 1 Pergoveris (450&nbsp;IU + 225&nbsp;IU)/0.72&nbsp;mL pre-filled pen and 7&nbsp;injection needles.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Only clear solution without particles should be used.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p dir="ltr">&nbsp;</p><p dir="ltr">For instructions on the use of this medicinal product, see the package leaflet, section &rsquo;Instructions for use&rsquo;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Merck Europe B.V.
Gustav Mahlerplein 102
1082 MA Amsterdam
The Netherlands

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                {April/2020}
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>